Ibrexafungerp's potent activity against multidrug-resistant fungal pathogen Candida auris confirmed in multiple pre-clinical studies
Ibrexafungerp may provide a therapeutic option for this emerging pathogen classified as a serious global health threat by the CDC
PR Newswire
JERSEY CITY, N.J., Oct. 15, 2018